Literature DB >> 30597074

Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases.

Rossella Elisei1, Antonio Matrone1, Laura Valerio1, Eleonora Molinaro1, Laura Agate1, Valeria Bottici1, David Viola1, Carlotta Giani1, Virginia Cappagli1, Francesco Latrofa1, Gabriele Materazzi2, Liborio Torregrossa3, Clara Ugolini3, Fulvio Basolo3, Cristina Romei1.   

Abstract

BACKGROUND: Multiple endocrine neoplasia type 2B (MEN 2B) is a very rare syndrome characterized by a very peculiar phenotype with mucosal neuromas, marfanoid habitus, and bumpy lips associated with medullary thyroid cancer (MTC) and pheochromocytoma (PHEO). Although the syndrome was first described 50 years ago, it is still diagnosed too late, when the MTC is metastatic and frequently when the PHEO has already developed. CASE PRESENTATIONS: We report on two cases of MEN 2B that were diagnosed too late, preventing a cure. The cases involve two females who were 25 and 12 years old. Both were previously treated for congenital skeletal abnormalities; however, despite their bumpy lips and mucosal neuromas, MEN 2B syndrome was not recognized. When they arrived at our center for both the presence of thyroid nodules and elevated serum calcitonin values, the MTC was already metastatic, and the older patient had already developed a bilateral PHEO. After 3 years and 1 year of follow-up, the two patients are still alive but with persistent structural and biochemical disease. DISCUSSION: These two cases show that knowledge of this syndrome is still insufficient and that the lack of knowledge impairs the ability to obtain an early diagnosis and cure. Because most patients with MEN 2B have no familial history, the only way to ensure a timely diagnosis is to recognize the MEN 2B phenotype on a clinical basis.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30597074     DOI: 10.1210/jc.2018-02102

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion.

Authors:  Carlotta Giani; Teresa Ramone; Cristina Romei; Raffaele Ciampi; Alessia Tacito; Laura Valerio; Laura Agate; Clara Ugolini; Michele Marinò; Fulvio Basolo; Alessandro Franchi; Simona Borsari; Angela Michelucci; Cesare Selli; Gabriele Materazzi; Filomena Cetani; Rossella Elisei
Journal:  Case Rep Endocrinol       Date:  2020-07-29

Review 2.  Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.

Authors:  Antonio Matrone; Carla Gambale; Alessandro Prete; Rossella Elisei
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 6.055

3.  Timely diagnosis of multiple endocrine neoplasia 2B by identification of intestinal ganglioneuromatosis: a case series.

Authors:  Medard F M van den Broek; Ester B G Rijks; Peter G J Nikkels; Victorien M Wolters; Robert J J van Es; Hanneke M van Santen; Bernadette P M van Nesselrooij; Menno R Vriens; Rachel S van Leeuwaarde; Gerlof D Valk; Annemarie A Verrijn Stuart
Journal:  Endocrine       Date:  2021-01-21       Impact factor: 3.633

4.  Thyroid Paraganglioma With Medullary Carcinoma: A Unique Combination in a Patient in Association With Multiple Endocrine Neoplasia Type 2B Syndrome With Prolonged Survival.

Authors:  Eleni Thodou; Theodossia Choreftaki; Theodora Kounadi; Labrini Papanastasiou; George Kontogeorgos
Journal:  Cureus       Date:  2022-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.